NCT03571516已完成3 期
A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 10
- 试验地点
- 8
- 主要终点
- Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
研究概览
简要总结
The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Months 至 12 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent by the parent or legal guardian.
- •Male or female infant 4 to 12 months corrected gestational age at screening.
- •Weight at least 5 kilogram (kg) and weight-for-length Z-score greater than -2 at screening and baseline.
- •Short bowel syndrome with dependence on parenteral support to provide at least 50% of fluid or caloric needs.
- •Stable PN requirements for at least 1 month prior to screening, defined as a less than or equal to (<=) 10% change in the weight-normalized PN total fluid and caloric intake, despite attempts to wean PN, not withstanding transient instability for events such as sepsis or interruption of central venous access.
- •Parent or legal guardian understands and is willing and able to fully adhere to study requirements as defined in this protocol.
排除标准
- •Previous treatment with teduglutide.
- •Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, etc.
- •Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce PN support, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
- •Inability to advance oral or enteral feeding due to lack of access to the gut, such as oral aversion in the absence of a feeding tube.
- •Intestinal obstruction or clinically significant intestinal stenosis.
- •Major gastrointestinal surgical intervention, such as serial transverse enteroplasty or major intestinal resection or anastomosis, within 3 months prior to screening or planned during the study period.
- •Unstable cardiac disease.
- •Renal dysfunction, defined as estimated glomerular filtration rate less than (<) 50 milliliter per minute (mL/min) per 1.73 square meter (m^2).
- •Biliary obstruction, stenosis, or malformation.
- •Clinically significant pancreatic disease.
- •Severe hepatic dysfunction or portal hypertension, defined by at least 2 of the following parameters:
- •International normalized ratio (INR) greater than (>) 1.5 not corrected with PN vitamin K
- •Platelet count <100×10^3/ microliter (mcL) due to portal hypertension
- •Presence of clinically significant gastric or esophageal varices
- •Documented cirrhosis
- •Persistent cholestasis defined as conjugated bilirubin >4 milligram per deciliter (mg/dL) (>68 micromoles per liter [mcmol/L]) over a 2 week period.
- •More than 3 serious complications of intestinal failure (example [e.g.], catheter-associated bloodstream infections, interruption of nutrition due to feeding intolerance, catheter-associated thrombosis, severe fluid or electrolyte disturbances) within 1 month prior to or during screening.
- •A history of cancer or a known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of gastrointestinal cancer (including hepatobiliary and pancreatic cancers).
- •Concurrent treatment with glucagon-like peptide-1 (GLP-1); glucagon-like peptide-2 (GLP-2); insulin-like growth factor-1 (IGF-1); growth hormone, somatostatin, or analogs of these hormones; or glutamine.
- •Participation in a clinical study using an experimental drug within 3 months or 5.5 half-lives of the experimental drug, whichever is longer.
- •Known or suspected intolerance or hypersensitivity to the investigational product, closely-related compounds, or any of the stated ingredients.
- •Any condition, disease, illness, or circumstance that, in the investigator's opinion, puts the participant at any undue risk, prevents completion of the study, or interferes with analysis of the study results.
研究组 & 干预措施
Teduglutide
Experimental
Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
干预措施: Teduglutide (Drug)
Teduglutide
Experimental
Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
干预措施: Standard Medical Therapy (Other)
Teduglutide
Experimental
Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
干预措施: Syringe (Device)
Teduglutide
Experimental
Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
干预措施: Needle (Device)
Standard of Care (SOC)
Other
Participants will receive standard medical therapy for 24 weeks.
干预措施: Standard Medical Therapy (Other)
Standard of Care (SOC)
Other
Participants will receive standard medical therapy for 24 weeks.
干预措施: Syringe (Device)
Standard of Care (SOC)
Other
Participants will receive standard medical therapy for 24 weeks.
干预措施: Needle (Device)
结局指标
主要结局
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
时间窗: Baseline, EOT/ET (up to Week 24)
Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.
次要结局
- Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS)(EOS (up to Week 28))
- Change From Baseline in Length Z-Score at Week 24(Baseline, Week 24)
- Change From Baseline in Weight-for-Length Z-Score at Week 24(Baseline, Week 24)
- Change From Baseline in Fecal Output at Week 24(Baseline, Week 24)
- Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 24(Week 24)
- Change From Baseline in Body Weight Z-score at Week 24(Baseline, Week 24)
- Change From Baseline in Average Total Urine Output at Week 24(Baseline, Week 24)
- Number of Participants With Positive Specific Antibodies to Teduglutide(Baseline, EOS (up to week 28))
- Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Plasma Concentration of Teduglutide at Nominal Time Points (Baseline at Pre-dose, and 1 Hour and 4 Hours Post-dose; 2 Hours Post-dose at Week 7)(Baseline: Pre-dose,1, 4 hours post-dose, and 2 hours post-dose at Week 7)
- Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)(From start of study treatment up to end of study (EOS) (up to Week 28))
- Change From Baseline in Head Circumference Z-Score at Week 24(Baseline, Week 24)
- Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
- Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)(Baseline, EOT/ET (up to Week 24))
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
Study of Teduglutide in Japanese Participants With Short Bowel SyndromeShort Bowel SyndromeNCT03663582Shire7
终止
2 期
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal TransplantationKidney TransplantationNCT06365437ITB-Med LLC33
已完成
2 期
A Dose Escalation Study in de Novo Renal TransplantationKidney TransplantationNCT04311632ITB-Med LLC13
已完成
3 期
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney DiseaseChronic Hepatitis CHepatitis C VirusCompensated CirrhosisSevere Renal ImpairmentEnd-stage Renal DiseaseNCT02207088AbbVie68
Unknown
1 期
A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male SubjectsHealthyNCT04485884HK inno.N Corporation42